Erytech collaborates on rare disease drug; Enterome creates diagnostics venture with Nestlé

⟶ France’s Erytech has forged a collaboration with Queen’s University in Canada on their eryminase program specifically for the treatment of arginase-1 deficiency, a rare and severe metabolic disorder related to arginine metabolism. “This is our second collaboration in the field of rare metabolic diseases that underscores the scope of our platform and its applicability to highly specialized and rare conditions beyond oncology,” said CSO Alexander Scheer.

⟶ Paris-based Enterome and Nestlé Health Science have created Microbiome Diagnostics Partners partnering on new diagnostics through to commercialization in multiple diseases areas, including inflammatory bowel diseases and liver diseases.

⟶ After getting hit with a series of setbacks over the years, the struggling Galena $GALE says it is making progress in launching “extensive interactions with numerous companies to explore options for monetizing some or all of its clinical development programs through a license or sale of the assets, and/or transforming the Company via a sale, merger, reverse merger, or business combination with another company.”

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->